Status:
COMPLETED
Effectiveness of Plasma Transfusions in Critical Care Patients
Lead Sponsor:
Ottawa Hospital Research Institute
Conditions:
Coagulation
Eligibility:
All Genders
Phase:
PHASE1
PHASE2
Brief Summary
Measuring the effectiveness of plasma transfusions in critical care
Detailed Description
Measuring the effectiveness of plasma transfusions in critical care
Eligibility Criteria
Inclusion
- ICU Admission
- INR \> 1.2
- Require FFP for active bleeding and/or prior to an invasive procedure
- Are able to provide consent or proxy consent
Exclusion
- Congenital or acquired coagulation factor deficiency
- Platelet count \< 50 x 109 /L and have NOT received subsequent platelet transfusion
- Consumptive coagulopathy (bleeding ≥ 3 sites and ↓ plts, ↓ fib, ↑ d dimer)
- Uncontrolled bleeding (6 or more units of blood in the last 6 hours)
- Receiving therapeutic doses of heparin/heparinoid (must be off for at least 6 hours)
- Have received clotting factor concentrates in the previous 24 hours
- Are expected to require surgery in the next 48 hours
- Survival expected to be less than 48 hours
- Currently enrolled in another study with a similar outcome
- Previous enrollment in this study
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2006
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT00302965
Start Date
April 1 2005
End Date
December 1 2006
Last Update
October 21 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ottawa Hospital
Ottawa, Ontario, Canada, K1H 8L6